Floatz logo

Allogeneic Natural Killer Cells

Mantle Cell Lymphoma

Paolo Caimi, MDCell therapyPhase 1Active
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
65/ 100

Competitive context

172 Active assets in the Mantle Cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Ruijin Hospital
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
Bendamustine
Czech Lymphoma Study Group
Phase 2BBB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 2BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Allogeneic Natural Killer Cells is also rated in:

primary peritoneal carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
44 / 100
View asset →
pancreatic adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →